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A tiered-layered-staged model for informed consent
in personal genome testing
Eline M Bunnik*,1, A Cecile JW Janssens2 and Maartje HN Schermer1
In recent years, developments in genomics technologies have led to the rise of commercial personal genome testing (PGT):
broad genome-wide testing for multiple diseases simultaneously. While some commercial providers require physicians to order
a personal genome test, others can be accessed directly. All providers advertise directly to consumers and offer genetic risk
information about dozens of diseases in one single purchase. The quantity and the complexity of risk information pose
challenges to adequate pre-test and post-test information provision and informed consent. There are currently no guidelines for
what should constitute informed consent in PGT or how adequate informed consent can be achieved. In this paper, we propose
a tiered-layered-staged model for informed consent. First, the proposed model is tiered as it offers choices between categories
of diseases that are associated with distinct ethical, personal or societal issues. Second, the model distinguishes layers of
information with a first layer offering minimal, indispensable information that is material to all consumers, and additional layers
offering more detailed information made available upon request. Finally, the model stages informed consent as a process
by feeding information to consumers in each subsequent stage of the process of undergoing a test, and by accommodating
renewed consent for test result updates, resulting from the ongoing development of the science underlying PGT. A tiered-
layered-staged model for informed consent with a focus on the consumer perspective can help overcome the ethical problems
of information provision and informed consent in direct-to-consumer PGT.
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INTRODUCTION
For a few years, a new generation of so-called personal genome testing
(PGT) companies has been marketing genome-wide SNP analysis and
whole genome sequencing directly to consumers. These companies
offer personal risks for dozens of diseases simultaneously, including
cardiovascular diseases, type 2 diabetes, psychiatric conditions and
many types of cancer. (Pathway: https://www.pathway.com; Knome:
http://www.knome.com; Counsyl: https://www.counsyl.com; 23andme:
http://www.23andme.com; deCODEme: http://www.decodeme.com)
Consumers can obtain this information through web-based services
with (Pathway: https://www.pathway.com; Counsyl: https://www.
counsyl.com) or without (23andme: http://www.23andme.com;
deCODEme: http://www.decodeme.com) the involvement of a medical
professional in the signing off on the test order. Consumers take a
cheek swab sample at home, send their sample to a molecular genetic
testing laboratory through the mail and receive their genetic test results
on a secure personal webpage.
Informed consent is an essential ethical requirement in genetic
testing1 and entails more than the signing of a consent form or the
ticking of a checkbox.2 From an ethical perspective, informed consent
is a communicative process of providing intelligible, preferably
tailored information, checking whether the patient—or in the case
of PGT, the consumer—has understood all relevant information,
complementing information found to be lacking, seeing again that all
informational needs have been met, and finally, asking for informed
consent. Most ethical conceptions of informed consent aim at
patients’ self-determination, autonomous decision-making and right
to choose,3 and at the protection against harm.4 As such, they are
much more demanding than legal ‘narration-followed-by-signature’
conceptions of informed consent.5 Most ethical theories of informed
consent agree that informed consent has at least three preconditions:
information, comprehension and voluntariness.6 At minimum,
persons giving informed consent should be legally and cognitively
capable of consenting, they should be free from external control, and
they should have adequate information and understanding of what it
is they are consenting to. Voluntariness as an ethical requirement may
be violated when consumers send in samples from third parties
without their consent. As an online health service, PGT can
be vulnerable to this form of misuse, which should naturally be
discouraged. For the remainder of this paper we will however not
focus on voluntariness, but on information and comprehension,
which are becoming increasingly pressing issues for PGT.
A traditional ethical conception of informed consent in the context
of clinical genetic testing requires consumers to receive pre-test
information about the test, the disease tested for, possible outcomes
and their significance, implications, limitations and risks of testing,
and many other relevant aspects.7 This conception cannot
be translated directly to the very different context of PGT: it will be
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difficult, if not impossible, for providers to produce and for
consumers—given the limited genetic health literacy among many
of them8—to process detailed, specific information on large numbers
of tests and diseases at the same time. Empirical research has not yet
brought consensus on whether consumers understand important
information about the (limited) clinical utility of a PGT.9,10
Especially in a direct-to-consumer context and without the help of
a medical professional, geneticist or genetic counsellor, information
about PGT is likely to be misunderstood by consumers.11,12
Therefore, the provision of adequate information and informed
consent are among the main concerns in PGT.13,14
Current guidelines for information provision in PGT14,15 do not
distinguish between information provision and informed consent.
They list a lot of information to be mentioned on providers’ websites,
but not all of this information pertains to informed consent. By
overloading consumers with less relevant information, informational
practices modelled on these guidelines may fail to convey the
important information elements that are necessary for informed
consent. None of the guidelines specifies how adequate informed
consent can be obtained.
The quality of information provision in PGT is high for some of
the leading companies, but not perfect.16 Most companies provide
abundant information, including educational materials and references
to the scientific literature. (Pathway: https://www.pathway.com;
Knome: http://www.knome.com; Counsyl: https://www.counsyl.com;
23andme: http://www.23andme.com) Yet, abundant information does
not equal adequate or relevant information and may mislead or
overwhelm consumers while failing to convey the key messages about
PGT. Company websites headline ‘improve your health’, ‘plan for the
future’, ‘take a more active role in managing your health’, or ‘23andme
saved my life,’ (23andme: http://www.23andme.com) thereby over-
stating the clinical utility of a large proportion of their testing offer.
They highlight the benefits of a PGT, while information about risks
and limitations is often difficult to locate.16,17 Information about risks
is mentioned in ‘Terms of Service’ or ‘Terms of Use’ agreements
(Pathway: https://www.pathway.com; Counsyl: https://www.counsyl.
com; 23andme: http://www.23andme.com) in which legal requirements
are laid out and which companies use instead of informed consent
procedures. Terms of Service agreements however are notoriously
lengthy and are unlikely to be read completely by each customer.15
Furthermore, these agreements can be said to aim at the legal
protection of companies rather than of consumers. They are not
necessarily designed to stimulate consumer understanding, nor do
they automatically constitute informed consent.
There is room for improvement in information provision16,17
and informed consent in a large proportion of PGTs offered.
This paper proposes a model for informed consent that is
suitable to handling the quantity and complexity of information in
PGT. The model is meant for online use and can be applied to both
direct-to-consumer and physician-mediated forms of commercial
PGT based on either genome-wide scans or exome or whole
genome sequencing. The advent of exome or whole genome
sequencing technologies in PGT may further expand the testing
offer and increase the clinical validity and utility of some of the
findings, and may thus exacerbate the need for a new model for
informed consent. We start from the assumption that it may not be
necessary or desirable to legally require professional counselling or to
ban direct access to PGT, and that although there is a moral
obligation for providers to facilitate informed consent, the
responsibility of actually making informed, autonomous decisions
regarding PGT, rests with the consumer.18
MODELS FOR INFORMED CONSENT
A wide range of models for and approaches to informed consent have
been developed in the history of medicine.4 Two main contrasting
approaches are specific consent, which in the context of genetic
testing requires consumers to be provided with elaborate and detailed
information about the testing procedure, the diseases tested for and
implications of testing, and generic consent, which focuses on general
information and common-denominator issues, such as general
characteristics of genetics and genetic testing, and common features
of the diseases tested for.19,20 Neither approach will be completely
suitable to PGT, because they both fail to promote two important
ethical aims of informed consent: the enabling of autonomous choice
and the protection against harms.21 Because of the complexity and the
quantity of the information offered in PGT, informed consent cannot
be fully specific. It will be impossible to provide consumers with
detailed information on all relevant aspects on all diseases tested for
in a PGT. Overloading consumers with detailed information will
undermine autonomous choice. On the other hand, informed consent
should not be too generic either. Consumers should at least know
what test results they will receive and be given the opportunity to opt
out of receiving test results which they anticipate may harm them or
which they do not wish to receive.18
A TIERED, LAYERED AND STAGED MODEL FOR INFORMED
CONSENT
An ethical approach to informed consent underlines the importance
of ensuring that consumers understand the clinical and emotional
impact PGT may have on them, and the implications for their
personal lives as well as for the lives of their family members.
Informed consent in PGT should aim at the provision of both
complete information (specific consent) and understandable informa-
tion (generic consent). The proposed model consists of a combination
of tiered, layered and staged models for informed consent, three
existing approaches to informed consent7,22,23 that all attempt to
provide information which is as complete as possible while remaining
understandable. Each of the three models will be described and
applied to PGT.
Tiered consent
Tiered consent is differentiated consent. The broad PGT offer can be
subdivided into tiers or categories of traits and diseases. Informed
consent can then be given for specified categories of diseases rather
than for the complete package. Differentiation of the testing offer can
help consumers make deliberate choices with regard to the informa-
tion they do or do not want to receive.
Tiered consent is currently widely used for biobanks and genomic
databases22,24 and for neonatal screening programmes.25 A few
‘binning’ or ‘packaging’ models have recently been suggested for the
return of results to research participants and for the interpretation of
whole genome sequencing.26–28 A ‘packages’ model distinguishes a
default package of research results and optional packages.26 The
‘default package’ contains information that should always be reported
back to participants such as directly life-saving information and other
information of high clinical utility indicating serious health
problems.26 The optional packages include data of moderate clinical
validity, data of reproductive significance and data of ‘personal or
recreational’ interest. One version of the ‘binning’ model consists of
five bins, in which the first bin contains medically actionable results,
the second results that have implications for family planning, the
third information that may be sensitive and unwanted (such as APOE
results), the fourth information that has clinical validity for diseases
Informed consent in personal genome testing
EM Bunnik et al
2
European Journal of Human Genetics
for which there are no therapeutic or preventive options and the fifth
bin, finally, contains all other ‘results’ or all data for which a clinical
interpretation is lacking or uncertain.28 In these models, the purpose
of the test is used as a criterion, for example: carrier status results that
can be used for reproductive decision-making are assigned a category
of their own. Interestingly, in the latter model the bins are defined
according to the emotional impact of results: there are separate bins
for sensitive or unwanted results and results lacking actionability. For
consumers, the purpose and the emotional impact of a test are likely
to be important criteria in deciding whether or not to take the
test—and to give informed consent. Empirical research is needed
to examine what criteria consumers find important or meaningful to
their decision-making processes.
In PGT, a tiered model for informed consent can be used to
distinguish between categories of diseases on the basis of both test
characteristics (eg clinical validity and utility) and disease characteristics
(eg severity, actionability, age of onset and the somatic or psychiatric
nature of the disease),29 as these characteristics are associated with
different clinical, psychological and social implications for consumers.
In a tiered process, consumers could for instance choose to obtain
only testing of high clinical validity and utility for its medical value
or—if they wish—only testing for non-medical traits for its informa-
tional or ‘curiosity’ value. Alternatively, they could choose to purchase
testing for somatic diseases only and leave out psychiatric diseases, or
for early-onset diseases only, not for late-onset diseases. Combinations
of test characteristics and disease characteristics may also be appro-
priate, for example: consumers could indicate that for very severe
diseases, they would only want to know their genetic risk if the test is
of high clinical validity. Providers of PGT could thus structure their
testing offer beforehand into tiers that are meaningful for consumers,
such as purposes of testing, severity of the diseases tested for,
actionability and emotional impact of test results.
At first glance, tiered consent might seem to pose practical
challenges to the business models of PGT providers. It might require
them to tailor their services according to consumers’ preferences.
Some companies have already differentiated their services and offer
‘cardio scans’ alongside ‘complete scans’ (deCODEme: http://www.de-
codeme.com) or pre-pregnancy planning services alongside drug
response services. (Pathway: https://www.pathway.com). Alternatively,
providers could conduct complete scans for all customers while
offering the possibility to opt out of receiving results for certain tiers.
Layered consent
Layered consent distinguishes between different layers of information.
The first layer pertains directly to informed consent and is indis-
pensable to informed consent. This information is explicitly offered to
all consumers and is kept minimal in order to increase the
effectiveness of its communication. There may be other information
elements that should be offered as part of a broader, general provision
of information,14,15 but these should be made available in second and
further layers of the information provision process. The concept of
layered consent is based upon the idea of extendable information:4
some information is offered to all consumers, whereas other, more
detailed information is accessible for consumers who actively seek it.
Information provision in public screening activities is often layered.23
An ethical approach to informed consent in PGT acknowledges that
the first layer should contain limited information in order to remain
comprehensible and manageable, and to avoid information over-
load.30 Many consumers will only read what is presented to them first
and will not seek additional information.31 Therefore, the first layer
should contain all crucial information, all the key messages about
PGT that are necessary for consumers’ understanding of PGT and for
their decision whether or not to take the test. For this reason, existing
guidelines for information provision in PGT may be too
encompassing as they include specific information such as the
location of the provider, funding arrangements and the evidence on
which interpretations of the test results are based.14,15 Although this
information may need to be available on PGT providers’ websites, it is
not part of the informed consent process itself and should not be
presented in the first layer, for it will distract consumers from what
they need to know in order to consent to PGT.
Informational needs for informed consent in PGT have not yet
been established. Following existing guidelines for information
provision in PGT14,15 and in clinical genetic testing,7 we expect that
consumers need to know at least the following eight information
elements in order to give informed consent: the purpose of the test,
the target group, limitations of the tests, risks and implications of
testing, tiers of the PGT, potential follow-up, data protection, and
where to find further and independent information (see Table 1). By
way of illustration, we discuss the most important elements briefly.
Consumers should understand the purpose of a genetic test at
the outset.32 PGT services are marketed for a variety of purposes,
ranging from prediction of risks for complex diseases (deCODEme:
http://www.decodeme.com) and pre-conception carrier screening
(Counsyl: https://www.counsyl.com) to pharmacogenomic informa-
tion, information on other, non-medical phenotypic traits, such as ear
wax type or eye colour, (23andme: http://www.23andme.com) and
nutrigenomic information (Pathway: https://www.pathway.com).
In order to manage consumers’ expectations and help them
understand correctly the nature of the PGT on offer, the purpose(s)
of PGT should be clearly addressed. In tandem with the purpose, the
target group(s) should be made explicit in the first layer.32 Possible
target groups are couples who intend to conceive, (Counsyl: https://
www.counsyl.com) healthy, asymptomatic adult individuals33 who
wish to know their genetic susceptibilities to complex diseases,
(23andme: http://www.23andme.com; deCODEme: http://www.
Table 1 A proposed contents of the first layer of the information
provision process
Information elements Examples
1 Purpose of the test Prediction of disease risks




2 Target group Adult consumers without health problems or
positive family history
Couples planning to conceive
3 Limitations Probabilistic versus diagnostic information
Test results may change over time
4 Implications and risks Psychological implications (eg anxiety)
Medical implications (eg unnecessary follow-up)
Social implications (eg insurance)
Implications for family members
5 Tiers Non-medical tests
Medical tests of limited versus high clinical
validity and utility
Medical tests subdivided into categories (tiers)
of diseases tested for
according to disease characteristics (eg severity,
age of onset)
6 Follow-up Follow-up testing and diagnostic workup for
clinically actionable test results
7 Data protection Access by third parties (eg researchers)
8 Sources of independent
information
Links to government/consumer/patient organisa-
tion websites
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decodeme.com) or consumers who are interested in genetics and who
wish to explore their genetic make-up out of curiosity. (23andme:
http://www.23andme.com)34 Through an explicit definition of the
target group, consumers with health problems and consumers who
worry about genetic conditions that run in their families can be clearly
informed that they may need to see a clinical geneticist instead of
purchasing a PGT.
Further, in order to enhance autonomous choice, consumers
should be given the opportunity to choose tiers so that they can
opt out of categories of diseases (eg diseases for which there are no
treatment options or psychiatric diseases). The company 23andme for
example does this by offering test results for hereditary breast cancer,
Alzheimer’s disease and Parkinson’s disease separately and asking
separate informed consent for each of these three diseases. (23andme:
http://www.23andme.com) Thus, the first layer of the information
provision process contains information that is of direct relevance to
the decision whether or not to proceed with PGT and to give
informed consent, such as the purpose and the target group of the
PGT, tiers from which to choose as well as key messages about the
follow-up and general limitations, risks and implications of PGT
test results.
Second and further layers may contain specific and detailed
information about the tiers of the PGT and the individual diseases
and traits tested for within these tiers, and about the clinical, personal
and social significance and implications of test results within these
tiers. Additional layers may further contain detailed information on
the testing procedure, the laboratory analysis, the technology and
algorithms used, the research findings on which risk calculations are
based and references to the scientific literature. They may also contain
additional information to improve understanding of the testing
service, such as general facts about genetics, categories of complex
diseases, disease prevention, genetic testing and its psychological and
social implications, for those who seek explanation, explication or
elaboration. Finally, they may contain legally relevant additional
information such as the location of the laboratory, advertising and
funding arrangements, details about policies for data security and for
what will happen to the database if the company goes bankrupt. As
the information offered in additional layers will be less crucial, the
moral obligation to provide such information will be less stringent
than the moral obligation to provide first-layer information. It follows
that there may be reasons to leave the precise contents of additional
layers to providers’ discretion.
The proposed outline of a layered model is meant as a starting
point for discussion. Geneticists, physicians, ethicists, policy-makers
and commercial providers may need to work together to examine
informational needs and preferences among consumers and
to determine what information is material to informed consent in
PGT. The aim of layered consent will now be clear: in order to avoid
overwhelming consumers with information, only information that is
essential to informed consent should be offered to all consumers in
the first layer, whereas further layers of information provision are
made available for those who desire more knowledge in order to
consent. In other words: in the first layer, consumers are made aware
of only the tips of all relevant icebergs, and they can find complete
images of all icebergs in further layers if they wish.
Staged consent
The idea of staged consent underlines that informed consent is a
process and takes time. People need time for consideration in order
to come to understanding decisions.35 In clinical genetics, time
is an essential feature of informed consent: counsellors allow for
time to pass between counselling and decision-making.7 In the
context of biobanks, stepwise informed consent is used to promote
comprehension.36 In PGT, a staged set-up of the information
provision process is already presupposed by a tiered model for
informed consent: as different risks, limitations, follow-up and
implications are associated with the different tiers, these tiers
require separate discussions before tier-specific consent can be
given. The tiered, layered and staged dimensions of the proposed
model are thus not fully separable and will intertwine.
The process of purchasing a PGT can be subdivided into three
informational and decisional phases, each to be concluded with
informed consent: first, informed consent to the PGT as a whole or to
certain tiers prior to buying the test; second, informed consent per
tier prior to receiving the test results; and third, informed consent
prior to receiving subsequent updates of test results. The general
contention of the idea of staged consent is that the passing of time
between these informational phases may allow for learning and
improve understanding.
First, the process of pre-test information provision preparing for
informed consent can be extended over time. The bulk of information
need not be presented all at once, but can be subdivided into
manageable portions, starting from general information about
benefits and limitations of PGT, followed by introductory informa-
tion about the tiers and concluded—upon demand—by specific
information about the diseases tested for within selected tiers and
associated risks and implications. This information may be repeated
and built or elaborated upon and thus constitute a learning
process. Models for a staged, integrated system of patient education
and informed consent have been envisioned also in the clinical
setting.37
PGT providers are already fulfilling part of the educational ideal
of staging: they present a riches of information on their websites,
(Counsyl: https://www.counsyl.com; Map My Gene: http://www.map-
mygene.com.) including educational materials (http://www.23andme.
com; deCODEme: http://www.decodeme.com) which can be accessed
freely and repeatedly by anyone who has access to the Internet.
Consumers can compare providers’ websites, search for informa-
tion, be taught the basics of genetics through tutorials, and in this
manner compile and tailor their own pre-purchase information
provision process. It remains important, however, that information
material to the actual informed consent is expressly presented to all
consumers (layered consent), and that informed consent is clearly
requested.
Second, informed consent itself may be staged as test results
may change over time. Many PGT companies offer their customers
regular updates of their test results as new genetic variants come
to be included in companies’ risk profiles and original test results
are reinterpreted, or as new associations are found between variants
and diseases, thus expanding companies’ testing offers. (23andme:
http://www.23andme.com) Customers are given the opportunity
to decide for each update whether or not they wish to view their
new test results. (23andme: http://www.23andme.com) With these
updates companies can rehearse or provide further information
on diseases tested for, before asking customers to give renewed
informed consent.
The proposed staged model emphasises that informed consent in
PGT, in accordance with the science which underlies it, may undergo
changes over time. Informed consent should be thought of as a
process rather than a once-and-for-all-time transaction. For this
reason, consumers should be able to withdraw from companies’
databases and subscription lists.
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In conclusion, a tiered, layered and staged model for informed
consent would structure the testing offer into tiers from which
consumers may choose understandingly, would prioritise information
such that consumers have sufficient knowledge of PGT generally and
its associated risks, limitations and implications, and would allow for
time to learn and time to consider. The structure of the Internet
commonly facilitates multi-layered and staged design; like many other
websites, PGT company websites are already layering information
(eg ‘click here to learn more’). (23andme: http://www.23andme.
com)16 With the help of information and communication
technologies, processes of information provision and informed
consent in PGT could be improved. It is not impossible that
enabling and encouraging consumers to make more well-considered
decisions regarding PGT will result in a smaller proportion of them
consenting to and purchasing PGT. As such, adequate procedures for
informed consent may run counter to companies’ business interests.
It is not yet known whether conflicts of interests will arise in practice.
Regardless, however, the moral obligation remains the same: to
mitigate the harms of testing and of misinterpretation and to
protect the value of autonomous choice.
CONCLUSION
Providers of PGT can be argued to have general moral obligations—
also in a commercial context—to offer information about their
services and to ensure that this information can be communicated
effectively. In order to protect consumers against harm and to enable
them to make autonomous choices, informed consent as an ethical
requirement is indispensable. PGT commonly involves a lot of
complex genetic information and thus poses difficulties for pre-test
information provision and informed consent. This paper proposes a
combined tiered-layered-staged model for informed consent that may
serve as a response to widespread worries about misinterpretation and
misunderstanding of PGT by consumers. The model is intended for
the commercial and online context in which PGT is currently offered
and in which face-to-face discussions with professional counsellors are
lacking. The proposed model focuses on the consumer perspective,
identifying the moments in which consumers make decisions about
PGT and the information they likely need in order to make informed
decisions about whether or not to consent to (certain tiers of) a PGT.
The proposed contents of the model are no more than preliminary. In
order to establish adequate tiered consent, academia, providers and
consumers may collaborate on the definition of categories of diseases
along the lines of clinical validity, purposes of testing, level of
potential harm, and personal, clinical and social implications. Also,
further research is needed to establish the exact contents of the first
layer of the information provision process prior to informed consent,
which is meant to contain only material, indispensable information
on PGT. Ideally, an interactive approach would allow providers to
check whether consumers have understood the key messages of PGT.
A tiered-layered-staged model for informed consent can be applied to
PGT in both direct-to-consumer and professionally mediated con-
texts, and help overcome the challenges regarding pre-test informa-
tion provision and informed consent encountered in commercial
PGT, now and in the future.
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